Henzl M R
Syntex Research, Palo Alto, California.
Am J Obstet Gynecol. 1992 Feb;166(2):757-61. doi: 10.1016/0002-9378(92)91709-j.
Clinical trials are under way to investigate the optimal use of nafarelin. In one series of studies, the effect of nasal mucosal inflammation and the concomitant use of nasal decongestants on the nasal absorption of nafarelin was evaluated in women with perennial rhinitis. Neither rhinitis nor concomitant therapy with a long-acting nasal decongestant substantially affected the nasal absorption of nafarelin. Other clinical studies are investigating strategies for second treatment of endometriosis or to improve the safety profile of nafarelin. In one trial, a second 3-month treatment course with nafarelin in patients with recurrent symptoms of endometriosis provided substantial pain relief. In another trial, preliminary information indicates that the addition of norethindrone to nafarelin in patients with endometriosis attenuates bone density changes and menopausal symptoms associated with nafarelin treatment.
关于那法瑞林的最佳使用方法的临床试验正在进行中。在一系列研究中，对常年性鼻炎女性患者评估了鼻粘膜炎症以及同时使用鼻减充血剂对那法瑞林经鼻吸收的影响。鼻炎和长效鼻减充血剂的联合治疗均未显著影响那法瑞林的经鼻吸收。其他临床研究正在探究子宫内膜异位症二次治疗的策略或改善那法瑞林的安全性。在一项试验中，对有复发性子宫内膜异位症症状的患者进行第二个为期3个月的那法瑞林治疗疗程，可显著缓解疼痛。在另一项试验中，初步信息表明，对子宫内膜异位症患者在那法瑞林中添加炔诺酮可减轻与那法瑞林治疗相关的骨密度变化和更年期症状。
